| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 8.80 | 35.4% |
| Total Income | 8.80 | 35.4% |
| Expenditure | 13.70 | 80.7% |
| PBT | -4.50 | 93.0% |
| Net Profit | -4.53 | 92.9% |
| OPM | -55.69% | |
| NPM | -51.53% | |
| EPS | 0.00 | 100.0% |
Zomedica Announces Q1 2026 Revenue of $8.8 Million, Up 35% YoY
07 May 2026 · 7 May, 2:28 am
Summary
Zomedica Corp. reported a record first quarter revenue of $8.8 million, reflecting a 35% annual growth. The company surpassed $8 million in first quarter revenue for the first time and delivered record year-over-year revenue for the 21st straight quarter. Performance was driven by strong performance of PulseVet® and Assisi® therapeutic device products, continued adoption of diagnostic offerings, and contributions from the Development Services segment. The company's cash burn for the quarter was down $1.1 million to $5.7 million.
Key Highlights
- 1
Zomedica's first quarter revenue grew by 35% to $8.8 million.
- 2
Diagnostics segment revenue increased by 73% year-over-year.
- 3
Consumable revenues grew to $5.5 million, up 22% from Q1 2025.
- 4
Development Services segment generated revenue of $2.0 million in the quarter.
- 5
Cash burn for the quarter decreased by $1.1 million to $5.7 million, a 15% reduction compared to Q1 2025.
- 6
Gross margin was 62% for the quarter, with the Therapeutic Device segment margin remaining strong at 70%.
Management Comments
Larry Heaton
"Delivering 35% growth and achieving record year-over-year revenue for the 21st consecutive quarter reflects the consistency of our execution and the growing demand for our products and services. Surpassing $8 million in first quarter revenue for the first time is a meaningful milestone, particularly given that, seasonally, the first quarter has historically been our lowest quarterly period from a revenue perspective" "With the momentum created through the first quarter of 2026, supported by the continued strength of our balance sheet, we believe we are positioned to execute on our growth strategy and scale our innovative product portfolio on a global scale"
Informational and educational content only. Not investment advice.